Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | BCL2A1 | Q16548 | 2/20 | 0.44 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | WEE1 | P30291 | 5/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14922244 | 0.86 | ALDH1A1 (0.48) | ALDH1A1LMNAHSD11B1HTR2CBCL2A1 | |
| SCHEMBL21358964 | 0.85 | LMNA (0.47) | ALDH1A1LMNAHSD11B1HTR2CXIAP | |
| SCHEMBL21358968 | 0.85 | LMNA (0.47) | ALDH1A1LMNAHSD11B1HTR2CXIAP | |
| SCHEMBL21358963 | 0.85 | LMNA (0.47) | ALDH1A1LMNAHSD11B1HTR2CXIAP | |
| SCHEMBL30952471 | 0.85 | LMNA (0.47) | ALDH1A1LMNAHSD11B1HTR2CXIAP | |
| SCHEMBL30952442 | 0.85 | LMNA (0.47) | ALDH1A1LMNAHSD11B1HTR2CXIAP | |
| SCHEMBL1901039 | 0.84 | ALDH1A1 (0.63) | ALDH1A1LMNAHSD11B1HTR2CBCL2A1 | |
| SCHEMBL1904488 | 0.84 | ALDH1A1 (0.63) | ALDH1A1LMNAHSD11B1HTR2CBCL2A1 | |
| SCHEMBL1901041 | 0.84 | ALDH1A1 (0.63) | ALDH1A1LMNAHSD11B1HTR2CBCL2A1 | |
| SCHEMBL22542066 | 0.83 | ALDH1A1 (0.61) | ALDH1A1LMNAHSD11B1HTR2CBCL2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | disclosed |
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | disclosed |
| US-7935703-B2 | Piperazines and piperidines as Mglur5 potentiators | ASTRAZENECA AB (SE) | 2011-05-03 | — | — | US | disclosed |
| EP-1979320-B1 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1979320-A2 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007087135-A2 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087135-A2 | PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023711-A1 | Piperazines and Piperidines as Mglur5 Potentiators | GRM5, GRM1, GRIN1 | ALDH1A1 1480/4885LMNA 4061/4885HSD11B1 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.